Trial · NCT04503551
Adverse events47
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 47
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Cataract | Eye disorders | PDS With Ranibizumab 100 mg/mL | 6 | 105 | 8 |
| other | Conjunctival haemorrhage | Eye disorders | PDS With Ranibizumab 100 mg/mL | 79 | 105 | 93 |
| other | Conjunctival hyperaemia | Eye disorders | PDS With Ranibizumab 100 mg/mL | 12 | 105 | 12 |
| other | Conjunctival oedema | Eye disorders | PDS With Ranibizumab 100 mg/mL | 10 | 105 | 10 |
| other | Diabetic retinal oedema | Eye disorders | PDS With Ranibizumab 100 mg/mL | 6 | 105 | 7 |
| other | Diabetic retinopathy | Eye disorders | PDS With Ranibizumab 100 mg/mL | 7 | 105 | 8 |
| other | Eye pain | Eye disorders | PDS With Ranibizumab 100 mg/mL | 9 | 105 | 15 |
| other | Foreign body sensation in eyes | Eye disorders | PDS With Ranibizumab 100 mg/mL | 9 | 105 | 9 |
| other | Iritis | Eye disorders | PDS With Ranibizumab 100 mg/mL | 10 | 105 | 10 |
| other | Ocular hypertension | Eye disorders | PDS With Ranibizumab 100 mg/mL | 7 | 105 | 9 |
| other | Punctate keratitis | Eye disorders | PDS With Ranibizumab 100 mg/mL | 10 | 105 | 14 |
| other | Vitreous detachment | Eye disorders | PDS With Ranibizumab 100 mg/mL | 9 | 105 | 10 |
| other | Vitreous haemorrhage | Eye disorders | PDS With Ranibizumab 100 mg/mL | 14 | 105 | 14 |
| other | COVID-19 | Infections and infestations | PDS With Ranibizumab 100 mg/mL | 16 | 105 | 16 |
| other | Sinusitis | Infections and infestations | PDS With Ranibizumab 100 mg/mL | 7 | 105 | 7 |
| other | Headache | Nervous system disorders | PDS With Ranibizumab 100 mg/mL | 9 | 105 | 11 |
| other | Hypertension | Vascular disorders | PDS With Ranibizumab 100 mg/mL | 8 | 105 | 8 |
| serious | Acute myocardial infarction | Cardiac disorders | PDS With Ranibizumab 100 mg/mL | 0 | 105 | 0 |
| serious | Angina unstable | Cardiac disorders | PDS With Ranibizumab 100 mg/mL | 1 | 105 | 1 |
| serious | Atrial fibrillation | Cardiac disorders | PDS With Ranibizumab 100 mg/mL | 1 | 105 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04503551/events